Equities

MDxHealth SA

MDXH:NAQ

MDxHealth SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.33
  • Today's Change0.06 / 2.64%
  • Shares traded8.01k
  • 1 Year change-30.65%
  • Beta--
Data delayed at least 15 minutes, as of Jul 03 2024 17:59 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

MDxHealth SA is a Belgium-based healthcare company which provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The Company's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.

  • Revenue in USD (TTM)75.33m
  • Net income in USD-39.90m
  • Incorporated2003
  • Employees300.00
  • Location
    MDxHealth SACAP Business Center, Rue d'AbhHERSTAL 4040BelgiumBEL
  • Phone+32 43642070
  • Fax+32 42597875
  • Websitehttps://mdxhealth.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Aileron Therapeutics Inc0.00-18.07m61.31m15.00--1.07-----3.19-3.190.005.420.00----0.00-31.05-65.99-33.17-75.37------------0.00------42.43------
Personalis Inc74.15m-92.61m61.81m223.00--0.5067--0.8336-1.89-1.891.512.350.31726.505.04332,493.30-39.62-28.84-46.08-34.7225.5928.65-124.90-96.013.56--0.0209--12.9714.234.43--6.80--
Anebulo Pharmaceuticals Inc0.00-9.35m62.24m2.00--12.48-----0.3633-0.36330.000.19220.00----0.00-91.51---104.28--------------0.00-------71.89------
RetinalGenix Technologies Inc0.00-3.73m62.51m0.00---------0.2124-0.21240.00-0.0850.00-------12,800.17-9,163.75---------------969.35--------46.58------
Vor Biopharma Inc0.00-120.23m62.80m168.00--0.5101-----1.78-1.780.001.800.00----0.00-54.09-45.79-57.42-48.98------------0.00-------27.98------
Serina Therapeutics Inc137.00k-20.96m63.36m4.00------462.46-14.07-14.070.0909-0.51210.0117--3.8634,250.00-179.27-194.46----67.8885.80-15,301.46-2,347.36---0.92741.70--317.65-36.69-41.49------
MDxHealth SA - ADR75.33m-39.90m63.58m300.00------0.8441-1.14-1.140.8428-0.03570.552811.066.95251,090.00-29.28-51.62-33.98-64.7262.7650.88-52.97-117.641.53-1.541.02--89.4319.842.14--30.13--
Precision BioSciences Inc57.53m-19.99m64.27m109.00--1.73--1.12-5.50-7.4113.765.380.2956--47.10527,807.30-10.27-35.35-12.94-44.22-----34.74-147.50----0.3764--94.1534.9641.67---32.01--
Bioqual Inc62.86m957.02k64.85m108.0067.761.6718.491.031.071.0770.2843.411.04--2.99--1.598.141.809.5214.1319.361.527.13----0.0021.43-5.2711.79-84.12-25.261.6010.76
Sellas Life Sciences Group Inc0.00-35.81m65.84m16.00--6.62-----1.12-1.120.000.17210.00----0.00-133.77-111.48-303.59-184.29-------1,289.42----0.00---100.00--9.59------
Champions Oncology Inc49.22m-9.73m65.93m230.00------1.34-0.7183-0.71833.64-0.15141.56--6.17214,017.40-30.91-5.40-96.45-11.8840.0947.96-19.76-3.09--------9.6921.63-1,073.54--18.50--
Genelux Corp8.00k-25.78m65.96m23.00--3.38--8,244.47-0.9811-0.98110.00030.56790.0004----347.83-131.24---246.21-------322,287.50------0.00---98.46---443.44------
Celularity Inc14.79m-181.41m66.22m225.00--1.95--4.48-10.51-10.510.83761.560.04982.292.0365,724.45-61.05---82.37--21.19---1,226.72--0.136618.400.5365---15.75--114.18------
Instil Bio Inc0.00-123.32m66.47m49.00--0.3229-----18.96-18.960.0031.650.00----0.00-33.63---35.47--------------0.2841------30.06------
Intensity Therapeutics Inc0.00-15.13m66.50m5.00--6.84-----1.10-1.100.000.7090.00----0.00-206.66---696.72--------------0.00-------56.45------
Sangamo Therapeutics Inc18.76m-328.05m66.82m405.00--1.16--3.56-1.86-1.860.10570.27840.0659--4.8646,311.11-115.20-26.09-139.17-31.04-----1,749.06-136.53----0.00--58.3415.85-34.09---13.25--
Data as of Jul 03 2024. Currency figures normalised to MDxHealth SA's reporting currency: US Dollar USD

Institutional shareholders

2.08%Per cent of shares held by top holders
HolderShares% Held
Bleichroeder LPas of 31 Dec 2022420.00k1.54%
BNP Paribas Asset Management Belgium SAas of 31 May 202448.71k0.18%
Perkins Capital Management, Inc.as of 31 Mar 202435.00k0.13%
XTX Markets LLCas of 31 Mar 202419.73k0.07%
Hood River Capital Management LLCas of 31 Mar 202419.33k0.07%
FAS Wealth Partners, Inc.as of 31 Mar 202416.33k0.06%
Geode Capital Management LLCas of 30 Apr 20245.26k0.02%
UBS Securities LLCas of 31 Mar 20241.60k0.01%
Dimensional Fund Advisors Ltd.as of 30 Apr 20241.27k0.01%
Dimensional Fund Advisors LPas of 31 Mar 2024843.000.00%
More ▼
Data from 31 Mar 2024 - 27 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.